FerroptoCure Inc. is developing new cancer drugs that work in a unique way. Our approach targets ferroptosis, a type of cell death caused by oxidative stress. Cancer cells often resist ferroptosis to survive and grow. Our drugs aim to overcome this resistance.
Key points about our work:
- We're targeting a mechanism that helps cancer cells survive and resist treatment
- Our drugs could potentially treat many types of cancer
- We've already begun Phase I clinical trials
- We aim to bring a major innovation to cancer treatment
Company Details
- Employees
- 2
- Founded
- 2022
- Address
- Tokyo, Jp
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://ferroptocure.com/en/
- HQ
- Tokyo
Ferroptocure Inc. Questions
Ferroptocure Inc.'s website is https://ferroptocure.com/en/
Ferroptocure Inc.'s LinkedIn profile is https://jp.linkedin.com/company/ferroptocure-inc
Ferroptocure Inc. has
2 employees.
View email and phone details for 2
employees at Ferroptocure Inc..
Ferroptocure Inc.'s industry is
Pharmaceutical Manufacturing
Ferroptocure Inc.'s top competitors are
Ibody Inc.,
Chiome Bioscience,
Intelvasc Inc,
E-Thermogentek,
Fertigo Medical Ltd.,
Spectracann,
Physiologas Technologies / フィジオロガス・テクノロジーズ,
Qritive,
Midriq Nbs, Inc.,
Trinear Inc..
Ferroptocure Inc.'s categories are Pharmaceutical Manufacturing
Ferroptocure Inc.'s founding year is 2022
